Key takeaways:

Antiviral treatment remains a cornerstone in preventing recurrence and reducing post-herpetic pain in herpes zoster ophthalmicus.

Adjunctive topical immunosuppressive treatment should also be considered.

COPENHAGEN, Denmark — Despite disappointing results from the Zoster Eye Disease Study, antiviral treatment remains the cornerstone in preventing recurrence and reducing post-herpetic pain in patients with herpes zoster ophthalmicus.

At the European Society of Cataract and Refractive Surgeons meeting Antoine Rousseau, MD, PhD, said adjunctive topical immunosuppressive treatment should be considered, but caution is recommended with the anti-varicella zoster virus (VZV) vaccine in this specific subgroup of patients.

“Nearly all of you have encountered the varicella zos

See Full Page